|
1
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T,
Sohara Y, Sugiyama Y and Mano H: Identification of the transforming
EML4-ALK fusion gene in non-small-cell lung cancer. Nature.
448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shinmura K, Kageyama S, Tao H, Bunai T,
Suzuki M, Kamo T, Takamochi K, Suzuki K, Tanahashi M, Niwa H, Ogawa
H and Sugimura H: EML4-ALK fusion transcripts, but no NPM-, TPM3-,
CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung
carcinomas. Lung Cancer. 61:163–169. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shinmura K, Kageyama S, Igarashi H, Kamo
T, Mochizuki T, Suzuki K, Tanahashi M, Niwa H, Ogawa H and Sugimura
H: EML4-ALK fusion transcripts in immunohistochemically
ALK-positive non-small cell lung carcinomas. Exp Ther Med.
1:271–275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takeuchi K, Soda M, Togashi Y, Suzuki R,
Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim
Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H and Ishikawa Y: RET,
ROS1 and ALK fusions in lung cancer. Nat Med. 18:378–381. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lipson D, Capelletti M, Yelensky R, Otto
G, Parker A, Jarosz M, Curran JA, Balasubramanian S, Bloom T,
Brennan KW, Donahue A, Downing SR, Frampton GM, Garcia L, Juhn F,
Mitchell KC, White E, White J, Zwirko Z, Peretz T, Nechushtan H,
Soussan-Gutman L, Kim J, Sasaki H, Kim HR, Park SI, Ercan D,
Sheehan CE, Ross JS, Cronin MT, Jänne PA and Stephens PJ:
Identification of new ALK and RET gene fusions from colorectal and
lung cancer biopsies. Nat Med. 18:382–384. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Casaluce F, Sgambato A, Maione P, Rossi A,
Ferrara C, Napolitano A, Palazzolo G, Ciardiello F and Gridelli C:
ALK inhibitors: a new targeted therapy in the treatment of advanced
NSCLC. Target Oncol. 8:55–67. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shaw AT and Solomon B: Targeting
anaplastic lymphoma kinase in lung cancer. Clin Cancer Res.
17:2081–2086. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
O’Bryant CL, Wenger SD, Kim M and Thompson
LA: Crizotinib: a new treatment option for ALK-positive non-small
cell lung cancer. Ann Pharmacother. 47:189–197. 2013.PubMed/NCBI
|
|
9
|
Rikova K, Guo A, Zeng Q, Possemato A, Yu
J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes
M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J,
Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi
SP, Gu TL, Polakiewicz RD, Rush J and Comb MJ: Global survey of
phosphotyrosine signaling identifies oncogenic kinases in lung
cancer. Cell. 131:1190–1203. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li C, Fang R, Sun Y, Han X, Li F, Gao B,
Iafrate AJ, Liu XY, Pao W, Chen H and Ji H: Spectrum of oncogenic
driver mutations in lung adenocarcinomas from East Asian never
smokers. PLoS One. 6:e282042011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kohno T, Ichikawa H, Totoki Y, Yasuda K,
Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y,
Iwakawa R, Ogiwara H, Oike T, Enari M, Schetter AJ, Okayama H,
Haugen A, Skaug V, Chiku S, Yamanaka I, Arai Y, Watanabe S, Sekine
I, Ogawa S, Harris CC, Tsuda H, Yoshida T, Yokota J and Shibata T:
KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 18:375–377.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bergethon K, Shaw AT, Ou SH, Katayama R,
Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang
R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW,
Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W and Iafrate
AJ: ROS1 rearrangements define a unique molecular class of lung
cancers. J Clin Oncol. 30:863–870. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Seo JS, Ju YS, Lee WC, Shin JY, Lee JK,
Bleazard T, Lee J, Jung YJ, Kim JO, Shin JY, Yu SB, Kim J, Lee ER,
Kang CH, Park IK, Rhee H, Lee SH, Kim JI, Kang JH and Kim YT: The
transcriptional landscape and mutational profile of lung
adenocarcinoma. Genome Res. 22:2109–2119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Davies KD, Le AT, Theodoro MF, Skokan MC,
Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M,
Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M and
Doebele RC: Identifying and targeting ROS1 gene fusions in
non-small cell lung cancer. Clin Cancer Res. 18:4570–4579. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly
ME, Gu TL, Mack JS, Silver MR, Zhou X and Haack H: Analysis of
receptor tyrosine kinase ROS1-positive tumors in non-small cell
lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res.
18:4449–4457. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yokota K, Sasaki H, Okuda K, Shimizu S,
Shitara M, Hikosaka Y, Moriyama S, Yano M and Fujii Y:
KIF5B/RET fusion gene in surgically-treated adenocarcinoma
of the lung. Oncol Rep. 28:1187–1192. 2012.
|
|
17
|
Yoshida A, Kohno T, Tsuta K, Wakai S, Arai
Y, Shimada Y, Asamura H, Furuta K, Shibata T and Tsuda H:
ROS1-rearranged lung cancer: a clinicopathologic and molecular
study of 15 surgical sases. Am J Surg Pathol. 37:554–562. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schmid K, Oehl N, Wrba F, Pirker R, Pirker
C and Filipits M: EGFR/KRAS/BRAF mutations in primary lung
adenocarcinomas and corresponding locoregional lymph node
metastases. Clin Cancer Res. 15:4554–4560. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ulivi P, Romagnoli M, Chiadini E, Casoni
GL, Capelli L, Gurioli C, Zoli W, Saragoni L, Dubini A, Tesei A,
Amadori D and Poletti V: Assessment of EGFR and
K-ras mutations in fixed and fresh specimens from
transesophageal ultrasound-guided fine needle aspiration in
non-small cell lung cancer patients. Int J Oncol. 41:147–152.
2012.
|
|
21
|
Thomas M, Kalita A, Labrecque S, Pim D,
Banks L and Matlashewski G: Two polymorphic variants of wild-type
p53 differ biochemically and biologically. Mol Cell Biol.
19:1092–1100. 1999.PubMed/NCBI
|
|
22
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
23
|
Rodig SJ, Mino-Kenudson M, Dacic S, Yeap
BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne
PA, Lynch T, Johnson BE, Iafrate AJ and Chirieac LR: Unique
clinicopathologic features characterize ALK-rearranged lung
adenocarcinoma in the western population. Clin Cancer Res.
15:5216–5223. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jokoji R, Yamasaki T, Minami S, Komuta K,
Sakamaki Y, Takeuchi K and Tsujimoto M: Combination of
morphological feature analysis and immunohistochemistry is useful
for screening of EML4-ALK-positive lung adenocarcinoma. J Clin
Pathol. 63:1066–1070. 2010. View Article : Google Scholar : PubMed/NCBI
|
